Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.


TSX:AEZS - Post by User

Aeterna Zentaris Inc
Bullboard Posts
User Avatar Image
(9)
•••
Comment by Volcom370on Sep 02, 2016 11:40pm
94 Views
Post# 25205126

RE:RE:Not so surprised

RE:RE:Not so surprised
TechOne wrote: You should have looked at it a bit more closely.. On March 30 when you posted this comment, share price closed CAD 4.16 .. It has been steadily inching up and today so far it is trading at CAD 5.40 ..  Volume on Toronto is high for this company but the real action is taking place on Nasdaq.. 

Shares on US side trading at 4.20 .. Volume is 518k ..  With 1.2m shares short and low shares outstanding, 2 Phase III trials completing by year end, with enough cash on the balance sheet and low valuation since the management has disappointed over the years, this one is poised for a lot of volatility and I bet, share price in high teens or more by late summer.. 


So how is it going ? Just teasing you. Still hoping does trial results are going to be good. Potential up side in the near future, but this thing could also go very wrong. Very speculative at this point, can't wait to see which side it going to go.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities